Verition Fund Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-15,900
Closed -$2.43M 3341
2024
Q4
$2.43M Hold
15,900
0.01% 1425
2024
Q3
$3.08M Hold
15,900
0.02% 1155
2024
Q2
$3.69M Hold
15,900
0.02% 905
2024
Q1
$3.43M Buy
15,900
+10,200
+179% +$2.39M 0.02% 912
2023
Q4
$1.47M Sell
5,700
-96,800
-94% -$23.8M 0.01% 989
2023
Q3
$26.3M Buy
+102,500
New +$27.4M 0.31% 48
2022
Q4
Sell
-120,000
Closed -$32M 2165
2022
Q3
$32M Buy
120,000
+100,000
+500% +$21.2M 0.36% 35
2022
Q2
$4.08M Hold
20,000
0.08% 336
2022
Q1
$4.21M Buy
20,000
+10,000
+100% +$2.17M 0.05% 480
2021
Q4
$2.4M Buy
+10,000
New +$2.57M 0.02% 761

Other funds holding BIIB

Verition Fund Management's BIIB Position: Q2 2026 in Review

Verition Fund Management opened a new position in Biogen (BIIB) in Q2 2026: 30,914 shares worth $6.68M. The stake represents 0.03% of the portfolio and ranks #523 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in BIIB as recently as Q4 2025.

Verition Fund Management first reported a position in BIIB in Q2 2013 and has held it in 42 quarters since. The position peaked at $54.5M in Q3 2023. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Verition Fund Management held 30,914 shares of Biogen worth $6.68M as of Q2 2026.
  • Biogen was a new Verition Fund Management position in Q2 2026.
  • Biogen made up 0.03% of Verition Fund Management's portfolio in Q2 2026, its #523 holding.
  • Verition Fund Management first reported a position in Biogen in Q2 2013 and has held it in 42 quarters since.
  • Verition Fund Management's Biogen position peaked at $54.5M in Q3 2023.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.